%0 Journal Article
%T EGFR V834L and L858R Comutation Is Associated With Response to Osimertinib in Non-Small-Cell Lung Cancer.
%A Giustini NP
%A Pritchard CC
%A Kamat NV
%A Menon MP
%J JCO Precis Oncol
%V 8
%N 0
%D 2024 Jul
%M 38991179
%F 5.479
%R 10.1200/PO.23.00215
%X Up-front osimertinib leads to clinical benefit in EGFR V834L and L858R comutated NSCLC.